retatrutide status fda Approval 2026: Everything We Know So Far Retatrutide approval: FDA status, clinical

Factors such as side effects, high out-of-pocket costs, injection fatigue and stigma around obesity treatment drive troves of patients some studies estimate roughly half or more to stop GLP-1s within a year and risk regaining the weight they lost

Heart palpitations can occur during GLP-1 therapy, but understanding the mechanisms and proper monitoring helps minimize risk

UChicago Medicine bariatric surgeon Vanessa Buie, MD, MBA, explains the benefits of surgery as a long-term alternative to taking GLP-1 medications

Whether a company manufactures products synthetically often depends on its current capabilities

How MNS Can Help Policy changes like this can create added administrative work and delays

The FDA approves Wegovy, the first oral GLP-1 pill, offering a new weight loss solution for those struggling with obesity and overweight.